Samsung Bioepis and Teva expand partnership to advance up to six potential biosimilar candidates

Samsung Bioepis Co., Ltd., a biopharmaceutical company committed to realizing healthcare that is accessible to everyone, and Teva Pharmaceutical Industries Ltd., a leading innovative biopharmaceutical company, announced

To access the full article, please log in or subscribe.